Syndax is ending development of Niktimvo in idiopathic pulmonary fibrosis (IPF) after the drug failed to meet endpoints in a Phase 2 placebo-controlled study. The decision brings another example of how difficult it has become to validate new efficacy signals in IPF, even when mechanistic rationale is strong. The company’s discontinuation also emphasizes how mid-stage reads increasingly function as gatekeepers for IPF capital allocation, particularly as competitors face heightened expectations for both clinical benefit and tolerability. From a portfolio perspective, the move is likely to redirect resources toward other respiratory or oncology programs, but the near-term impact is a reduced pipeline of ILD candidates competing for future trials.